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Introduction
Multi-drug resistant tuberculosis (MDR-TB) is an
increasing health problem in Pakistan. According to World
Health Organization (WHO),1 the estimated cases of MDR
tuberculosis in Pakistan are 3.4% and 36% in new and
previously treated cases of tuberculosis respectively. Globally,
Pakistan is ranked 8th in terms of estimated number of
tuberculosis (TB) cases, with an incidence of 181/100,000
persons.  
The treatment of MDR tuberculosis is difficult because
it is expensive, prolonged and complicated which in turn result
in poorer outcome.2 There is no reported data from Pakistan
on treatment outcome of MDR tuberculosis.
We are presenting our experience in treating a large
series of patients with MDR pulmonary tuberculosis.
Patients & Methods
This observational study was done at Ojha Institute of
Chest Diseases (OICD) from 1996 to 2006. The Ethical
review committee of OICD approved the study. OICD is a
350-bedded postgraduate institute with five chest clinics in
Karachi. It registers 4500-5000 TB patients annually and
provides them treatment using DOTS (Directly Observed
Treatment Short course) strategy. The Institute is the pioneer
in providing treatment for MDR TB patients since 1996. 
We reviewed the records of 579 culture proven
admitted cases of MDR pulmonary tuberculosis patients
registered from 1996 to 2006. Susceptibility testing and drugs
that had not been used in the past guided therapy. We
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Abstract
Objective: To assess the outcomes of pulmonary multidrug-resistant tuberculosis (MDR-TB) patients treated at
Ojha Institute of Chest Diseases (OICD), a reference hospital for TB in Karachi, Pakistan.
Methods: Clinical study for the period 1996-2006, with follow-up until June 2007 was performed. All the culture
and sensitivity proven cases of MDR pulmonary TB were initially admitted for 3-6 months till the sputum
converted negative. Treatment regimen was decided on individual basis, and included 4-6 drugs. Supervised
treatment was given to all patients during the hospitalization. After discharge from the hospital, patients were
followed at monthly interval at the outpatient department of OICD for 18 months total.
Results: Five hundred and seventy nine adult patients (59.93% male) with mean age of 32.44 ± 12.63 years
were studied. All patients had a history of treatment with first line anti-tuberculosis drugs. Treatment was
successful in 227 (39.2%). The mortality rate was 27(4.6%) during hospitalization. During admission 83(14.3%)
left treatment and 239 (41.2%) were lost to follow-up during treatment. Treatment failure was observed in three
patients.
Conclusion: The treatment success rate in this study is satisfactory but high default rate is a challenge in the
management of MDR tuberculosis (JPMA 59:694; 2009).
administered minimum four drugs (range 4 to 7 drugs; median
5 drugs) during the intensive phase including one injectable
aminoglycoside (mostly Kanamycin) and Quinolone
(Ofloxacin in most of the patients) from the 2nd line and also
included the sensitive drug if any from the first line according
to the sensitivity results on individual basis. During the
continuation phase we used 3 to 4 oral drugs according to the
sensitivity from the first and 2nd line drugs. The dosages used
are mentioned in Table-1.
During hospitalization the sputum for AFB (Acid
Fast Bacilli) smear were done monthly. AFB cultures
were done every three months. Patients remained in the
hospital until the sputum smear became negative.
Supervised treatment was given to all patients during
hospitalization. Every possible effort was made to
continue therapy in patients who developed adverse drug
reactions. Appropriate measures were taken to combat
side effects.
After a period of initial hospitalization, patients
were discharged with one month of medications and
advised to report to MDR clinic within one month. They
were followed in outpatient clinic monthly. Drugs for
one month were pre-packed and handed over to the
patient. The patients were evaluated for clinical,
microbiological and radiological response regularly.
They were also evaluated for side effects of the
medications. Patients were followed by sputum
microscopy (three specimens) every three-months and
treatment continued for a total of eighteen months. At
the end of treatment, patients were asked for follow up
at 3, 6 and 12 months or any other time if they developed
respiratory symptoms suggestive of tuberculosis that did
not resolve in three weeks with treatment or referred
from their general practitioner.
The MDR TB treatment outcome definitions were
used as follows:
Successful outcome: Patient who completed treatment
and consistently had negative smear (Performed every three
months in continuation phase). 
Treatment default: Patients who did not receive
treatment for > 2 consecutive months were defined as having
defaulted treatment.
Treatment failure: Patients whose smear was positive
at the end of six month or whose > 2 smears were positive
during final 12 months. 
Death: Patients who died due to any cause during
treatment. 
LAMA (left against medical advice): Patients who left
hospital against medical advice during initial hospitalization
phase. 
The definition of successful treatment in this study
not in line with the WHO recommended definition which
recommends culture results as gold standard.3 The
limitation was non-availability of large-scale culture
facility.
SPSS version 14 was used to analyze the data. The
results are presented as mean with standard deviation.
Results
A total of five hundred and seventy-nine patients
with MDR pulmonary Tuberculosis were registered.
Three hundred and forty seven (59.93%) were male and
347 (40.07%) were female; their mean age was 32.44 ±
12.63 (range 15-78 years). Twelve percent of the patients
had unilateral disease while remaining had bilateral
extensive fibrocavitary disease. In all patients there was
history of multiple courses of ATT intake including the
full course of category 2 regimen. The comprehensive
detail of previous treatment was not available in most of
the patients.
On initial sensitivity report 326 (56.5%) of patients
were resistant to all 5 first line drugs. The median number of
drugs received was 5 (range 4 to 7). The median duration of
hospital stay was 3.8 months. The total duration of treatment
was 18 months.
Response to Treatment: 
Successful outcome was seen in two hundred and
twenty seven patients i.e. 227/579 (39.20%). Eighty-
three patients (14.33%) left hospital against medical
advice (LAMA) during initial hospitalization, 239
(41.27%) defaulted after discharge, 27 (04.66%) expired
due to tuberculosis, while three patients (0.51%)
remained positive at the end of one year. Attempts were
made to contact patients by phone. However, either their
phone number was incorrect or the patient deliberately
did not attend the call. Due to non-availability of
physical facilities for follow up of defaulted patients, the
defaulters could not be traced. All patients (except three)
i.e. 466/579 (80.48%) were smear negative at the time of
discharge from hospital.
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Table-1: Second line anti-tuberculosis drugs with dosage.
Drug Dose
Kanamycin 15mg/Kg/day im (single dose)
Ethionamide 15 mg/Kg/day (Single or two divided doses)
Cycloserine 15 mg/Kg/day (Single or two divided doses)
PAS 120 mg/Kg/day (Two divided doses)
Ofloxacin 15 mg/Kg/day (Single or two divided doses)
Thiacetazone 150 mg/day (Single dose)
Microbiological Response to Treatment:
Most of the patients 416/579 (71.84%) converted
to smear negative at three month, 111 (19.17%) at 04
months while 49 patients (08.46%) took up to six months
to convert. Three patients were smear positive at the end
of one year so they were labeled as treatment failure.
In Table-2 detailed outcome analysis of different
regimens is given. The most successful regimens in patients
resistant to all five first line drugs were kanamycin,
ethionamide, ofloxacin, cycloserine and para-
aminosalicylic acid (KEthOfCP) and kanamycin,
ethionamide, ofloxacin, pyrazinamide and para-
aminosalicylic acid (KEthOfZP) with 50% & 53%
successful outcome respectively. In the first group, total
number of patients was small. "Other" regimen consisted of
multiple regimens of first and second line drugs according
to individualized initial culture report. 
Two hundred and thirty nine patients defaulted in the
study. They defaulted during the follow up period. Fifty-
three patients (21.33%) defaulted within two to three
months of discharge, 108 patients (45.18%) defaulted
during month 7-12 (Of treatment) while 80 patients
(33.47%) defaulted during month 13-18.
Side effects:
During hospital stay, eighty-eight patients (15.19%)
developed side effects due to medications. They were
managed accordingly but in thirty-one patients (5.35%) one or
more antituberculosis drug was discontinued (Table-3).
Among the minor side effects the most common were Gastro-
intestinal upset i.e. bloating, abdominal pain, nausea, vomiting
and diarrhoea. Besides dizziness, anorexia, joint pain,
headache and depression was also seen.
The follow up at three and six month had records of
only 119 (52.42%) and 48 (21.14%) and all were smear
negative. 
Relapse Rate:
During the study period, eight patients (03.52%)
reported with positive sputum among those who successfully
completed the treatment. The gap between completion of
treatment and relapse was between months 2 to 8.  
Discussion
This is the first largest study from Pakistan on
treatment outcome of MDR TB patients. The treatment
success rate in this study was 39.2% (227/579). Lockman4
reported cure rate (defined as "Completed >6 months of
therapy and had a negative AFB smear result at end of
treatment") of 37% (17/46) which is compatible to our study.
Marie et al5 from France reported 33.33% success rate in
their 51 cases. Goble et al6 had an overall response rate of 56
percent after excluding default and death, but if the overall
response of the total patient number is calculated then the
rate becomes 87/171 (50.87%). Other authors have also
reported low success rate7-10 varying from 44-51.2% in
which full cohort was reported.  Our results are not
comparable to these studies because of the difference in the
treatment success definition. Cultures are more sensitive
than smear results and it is quite possible that our results of
treatment success would have been lower if we had used the
criteria of culture in follow up.
The other observation in this study was a high
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Table-2: Treatment outcome analysis based on regimen.
Regimen/No of patients Successful outcome Default LAMA Death Treatment Failure
KEthOfCtz/49 14 (28.5%) 19 (38.7%) 12 (24.4%) 03 (6.1%) Nil
KEthOfCtzC /53 23 (43.39%) 16 (30.1%) 10 (1.88%) 04 (7.54%) Nil
KEthOfCtzC /09 04 (44.44%) 03 (33.33%) Nil 02 (22.22%) Nil
KEthOfCP/70 35 (50%) 31 (44.28%) 01 (1.42%) 03 (4.28%) Nil
KEthOfP /62 15 (24.19%) 42 (67.74%) 01 (1.61%) 04 (6.45%) Nil
KEthEZOf/101 43 (42.57%) 24 (23.76%) 29 (28.71%) 05 (4.95%) 01 (0.99%)
KOfEthZP/15 08 (53.33%) 06 (40%) Nil 01 (6.66%) Nil
KEthCtzOfP/27 12 (44.44%) 13 (48.14%) 01 (3.70%) 01 (3.70%) Nil
Others/193 73 (37.82%) 84 (43.52%) 29 (15.02%) 05 (2.59%) 02 (1.03%)
Total 227 238 83 28 03
K: Kanamycin, Eth: Ethionamide, Ofl: Ofloxacin, C: Cycloserine, P: ParaAminosalicylic Acid, E: Ethambutol, Z: Pyrazinamide, Ctz: Combination of INH (Isonicotinic acid
hydrazide) and Thiacetazone, Others: Regimen not fitting in any of the above, LAMA: leave against medical advice.
Table-3:  Discontinuation of ATT due to adverse effects.
Drug No. Discontinued/total Reason for discontinuation
received (%) (no. of patients)
Cycloserine 16/194 (8.24%) Homicidal attempt (1),
Psychosis, aggressive
behaviour, suicide attempt (1)
Kanamycin 07/623(1.12%) Deafness
Ethionamide 01/497 (0.20%) Severe vomiting
PAS 04/249 (1.60%) Hypothyroidism with goiter,
Hepatitis
Thiacetazone 3/252 (1.19%) Abdominal pain
default rate. Out of 579 patients, a total of 322 (55.6%)
defaulted including both during hospitalization and
afterward.  Lockman et al4 from Estonia reported high
default rate in both of their MDR and drug susceptible
groups i.e. 16/46 (35%) and 19/46 (41%) respectively.
Other authors have   also reported high   default rates of
39%11 and 28.9%7 from Korea, 29.1%8 from Taiwan
and15.38%12 from India. We believe that the reason for
default/discontinuation of therapy in our setting is
improvement in symptoms as evidenced by high default rate
in the latter half. The possibilities of discontinuation due to
side effects, long distance to collect medicine, natural
disasters like floods cannot be ruled out. To combat these
issues we suggest: Intense motivation of patients at the time
of registration and discharge, telephonic access to the
medical officer for issues arising when patient is at home.
Beside after discharge Directly Observed Therapy (DOT) is
the most important single measure in decreasing the default
and in completing the therapy. In this regard liaison with TB
control programme through their DOTS treatment centers
will help. Incentives in the form of cash or promotion in
service will motivate the staff for this additional work. If
any patient defaults, it will be possible to trace and rectify
the issues responsible for the default. Besides training of
doctors and paramedics in the management of TB generally
and MDR TB specifically is essential.
We considered the correlation between past
treatment history and response to current treatment but in
Pakistan most of the General Practitioners prescribe
Anti-tuberculosis treatment (ATT) on radiological
ground, without sputum examination. Patients consult
another doctor in case symptoms do not improve or side
effects are encountered. In some cases they consult a
third doctor on recommendation of some friend or family
member. Most of the patients do not keep the record. End
result is either same drug in different dose or sometime
addition of one more drug which in turn results in more
resistance.
It has been reported13 that patients who receive initial
therapy in a hospital had significantly higher treatment
completion rates (79%) than those treated as outpatients alone
(48%, p < 0.001). Our treatment completion rate was low in
spite of all patients being admitted in the initial phase.
It is recommended13 that early surgical intervention
(e.g., within 6 months after intensive chemotherapy) could be
beneficial, even if the patient has a positive result of smear or
culture. None of our patient underwent surgery due to non-
availability of proper surgical facility otherwise results would
have been better as studies14-16 have shown good results when
chemotherapy was combined with surgery. 
The relapse rate is quite low in this study. This could
be because if the patient who benefitted from the treatment
center would report to the same center, once symptoms
recurred. The possibility of death has to be considered. It is
possible that the patients did not develop a relapse or did not
report due to the long distance and financial reasons.
The limitation of this study was that the patients were
followed up with sputum smear only as the facility for AFB
culture on a large scale was not available. It was therefore
presumed, that any patient excreting bacilli was positive or
became positive if he/she was excreting viable bacilli. The
doubling time of Mycobacterium tuberculosis is 16-24 hours17
and for sputum to be positive on smear, the bacillary count
should be 10,000 bacilli/ml of sputum.18 Others19 claim that
with optimal laboratory conditions, smear can be positive with
only 100-1000 bacilli/ml. If one hundred bacilli are present in
the lung then after one month the count will increase to
>10,000 and at next examination smear will become positive.
The other limitation was lack of follow up after completion of
treatment. In resource-limited countries, where default during
treatment is high, it is difficult to expect a regular follow up
after completion of treatment.
Conclusion
This is the first large study on MDR TB treatment
outcome from Pakistan, a high TB burden developing country.
The treatment success rate in this study is low and not
comparable to other large studies due to the use of smear
results rather than the culture in follow up period. Although
the initial microbiological response to the treatment was
excellent but defaulting from treatment is a major challenge in
the treatment of MDR TB in our cohort of patients. Strategies
are needed to reduce default rate in this group of patients.  
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